Shaping the Future of Biopharma EHS
The only global, industry-focused EHS for Biopharma Summit brings together 100+ EHS leaders to hear how AstraZeneca, Amgen, Novartis, Pfizer and AbbVie are tackling critical safety challenges. Explore process safety beyond OSHA PSM, exposure controls for ADCs and radiopharmaceuticals, PFAS and RCRA compliance, and waste reduction strategies.
With 17+ new speakers and 11+ new speaking companies, discover fresh approaches through practical case studies and brand new interactive sessions. Test your decision making in Hazzard a Guess and exchange real AI applications in the AI Exchange, while benchmarking strategies with peers who understand the unique challenges of biopharma EHS.
What's New for 2026?
New for 2027 | Hazzard a Guess & AI Exchange
Put your EHS decision making to the test in realistic biopharma safety scenarios with Hazzard a Guess, and exchange real AI applications, prompts and implementation lessons with industry peers in the interactive AI Exchange.
Build Safer Biopharma Facilities & Strengthen Contractor Safety from Design to Delivery
Discover how Amgen and AbbVie are approaching EHS integration into greenfield and brownfield capital projects, contractor prequalification and onboarding to prevent incidents and maintain safety standards without delaying construction.
Reduce Waste Costs & Stay Ahead of Environmental Regulations
Discover how MannKind, AbbVie and Nitto Denko Avecia are reducing regulated waste volumes, implementing measurable sustainability improvements and navigating PFAS and RCRA compliance challenges.
Turn Occupational Health Data into Earlier Interventions & Measurable Business Value
Hear from Amgen on leveraging medical surveillance, injury reports and employee health trends to identify emerging workforce risks, develop meaningful leading indicators and demonstrate the value of preventative occupational health programmes.
Strengthen Exposure Controls for Emerging Drug Modalities
Get hands on with experts from Charles River Laboratories and Dana-Farber Cancer Institute to explore occupational exposure banding, quantitative exposure assessment and containment strategies for ADCs, cell and gene therapies and radiopharmaceuticals.
Attending Companies Include